CIA
CRL icon

Cape Investment Advisory’s Charles River Laboratories CRL Stock Holding History

Cape Investment Advisory’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.4K Buy
+240
New +$42.7K 0.01% 479
2026
Q1 		– Sell
-204
Closed -$40.7K – 407
2025
Q4 		$40.7K Buy
204
+4
+2% +$726 0.01% 464
2025
Q3 		$31.3K Buy
200
+4
+2% +$635 0.03% 273
2025
Q2 		$29.7K Buy
196
+8
+4% +$1.07K 0.01% 449
2025
Q1 		$28.3K Buy
188
+30
+19% +$5.03K 0.01% 423
2024
Q4 		$29.2K Buy
158
+20
+14% +$3.85K 0.01% 421
2024
Q3 		$27.2K Sell
138
-4
-3% -$831 0.01% 408
2024
Q2 		$29.3K Sell
142
-51
-26% -$11.6K 0.01% 377
2024
Q1 		$52.3K Buy
193
+18
+10% +$4.3K 0.02% 303
2023
Q4 		$41.4K Buy
175
+2
+1% +$393 0.02% 381
2023
Q3 		$33.9K Hold
173
– – 0.02% 357
2023
Q2 		$36.4K Buy
173
+136
+368% +$27.1K 0.02% 339
2023
Q1 		$7.47K Buy
+37
New +$8.38K ﹤0.01% 593

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Cape Investment Advisory's CRL Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Charles River Laboratories (CRL) in Q2 2026: 240 shares worth $54.4K. The stake represents 0.01% of the portfolio and ranks #479 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in CRL as recently as Q4 2025.

Cape Investment Advisory first reported a position in CRL in Q1 2023 and has held it in 13 quarters since. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Cape Investment Advisory held 240 shares of Charles River Laboratories worth $54.4K as of Q2 2026.
  • Charles River Laboratories was a new Cape Investment Advisory position in Q2 2026.
  • Charles River Laboratories made up 0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #479 holding.
  • Cape Investment Advisory first reported a position in Charles River Laboratories in Q1 2023 and has held it in 13 quarters since.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.